Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | MST1R | Q04912 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FES | P07332 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | FGR | P09769 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948094 | 0.85 | MET (0.48) | METIGF1RKDRMST1RINSR | |
| SCHEMBL14146495 | 0.78 | TRPV4 (0.39) | METIGF1RKDRMST1RINSR | |
| SCHEMBL2950370 | 0.76 | MET (0.47) | METIGF1RKDRMST1RINSR | |
| SCHEMBL2945012 | 0.76 | MET (0.48) | METIGF1RKDRMST1RINSR | |
| SCHEMBL2953840 | 0.71 | MET (0.59) | METIGF1RKDRMST1RINSR | |
| SCHEMBL14075519 | 0.71 | MET (0.43) | METIGF1RKDRMST1RINSR | |
| SCHEMBL2946771 | 0.71 | MAPK1 (0.49) | KDM4EALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL2947202 | 0.70 | KIT (0.57) | METKDRMST1RINSRJAK2 | |
| SCHEMBL30975172 | 0.70 | MET (0.64) | METIGF1RKDRMST1RINSR | |
| SCHEMBL2381779 | 0.69 | GLA (0.49) | KDRJAK3LCKMAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759344-B2 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759344-B2 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759344-B2 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2118069-A2 | BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | AMGEN INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008086014-A2 | BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234268-A1 | Bis-aryl amide derivatives and methods of use | MET, REL, NAT1 | MET 1/4885IGF1R 216/4885KDR 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.